The short-term effect of pretreatment with ATD on serum thyrotrophic-receptor auto antibodies levels after 131I therapy in patients with graves' disease

Objective: To evaluate the short-term effect of pretreatment with ATD on serum TRAb levels after 131I therapy in patients Graves' disease. Methods: Serum TRAb levels were measured with radioimmunoassay both before and 3 or 6 months after 131I treatment in (1) 74 patients frented with 131I therapy only and (2) 109 patients who had been freated with standard ATD regimen for 1.5 years before the present 131I therapy. Results: After treatment, the serum TRAb levels in both two groups increased significantly than the levels before (P<0.001). There were no significant differences between the two groups 3 and 6 months after treatment(P>0.05). Conclusion: 3 and 6 months after 131I therapy, serum TRAb levels were significantly higher than those before treatment in both groups. There is no short-term effect of ATD pretreatment on serum TRAb levels after 131I therapy in patients with Graves' disease. (authors)